Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
about
Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect.Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions.Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs.Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic.Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.The Proton Pump Inhibitor Non-Responder: A Clinical ConundrumThe pharmacology of esomeprazole and its role in gastric acid related diseases.Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.Gastric acid, calcium absorption, and their impact on bone health.Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease.A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease.Intragastric acidity during administration of generic omeprazole or esomeprazole - a randomised, two-way crossover study including CYP2C19 genotyping.The patient with refractory gastroesophageal reflux disease.Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.Safe use of proton pump inhibitors in patients with cirrhosis.
P2860
Q33891049-0E4150C5-AE85-4E95-86C2-A06BCEFB0C81Q34233142-4F5A60D6-E616-4E8A-B557-60CA61B67F6DQ34636475-3F827F85-82E5-4A1B-A7C0-AAC9B42290CFQ36723844-19BEA19E-FF8B-42C7-9F75-16D01C6B8FEAQ36729180-227030F1-A85B-4FF4-BC5C-B274F48B6706Q36752080-14C83F3D-9A20-4266-881C-4DAC9F6C5B42Q37552951-426317F5-6098-4405-8F7F-8DDE6C937E74Q38032920-F9C6DE0A-EDAE-45FB-AC8B-29D8CCC56664Q38072903-AAB098B6-AE23-4A1B-BAA8-9802FC40234EQ38229080-E6DE9A95-CBC3-47E1-9209-837DE9603F49Q38599606-FAA8D8D2-1B70-4DFE-9917-73C4A247C3F3Q51622395-5A56ACE4-AC88-42A4-8AFB-946515511127Q51930058-B1B3857E-2C20-4C5A-8995-8BCD10809FC4Q55280841-F4AE46FB-D31F-443B-80EB-EA3ABA632377Q55718075-DCF6D01A-DF0F-491C-A1D7-FC38FCC91CD4
P2860
Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Esomeprazole-induced healing o ...... ical and pharmacokinetic data.
@ast
Esomeprazole-induced healing o ...... ical and pharmacokinetic data.
@en
type
label
Esomeprazole-induced healing o ...... ical and pharmacokinetic data.
@ast
Esomeprazole-induced healing o ...... ical and pharmacokinetic data.
@en
prefLabel
Esomeprazole-induced healing o ...... ical and pharmacokinetic data.
@ast
Esomeprazole-induced healing o ...... ical and pharmacokinetic data.
@en
P2093
P50
P1476
Esomeprazole-induced healing o ...... ical and pharmacokinetic data.
@en
P2093
Andreas Leodolter
Gerhard Treiber
Matthias Schwab
Ulrich Klotz
P304
P356
10.1016/J.CLPT.2005.08.017
P407
P577
2005-12-01T00:00:00Z